Literature DB >> 22878428

Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.

Dirk Dressler1.   

Abstract

Botulinum toxin (BoNT) has gained widespread use for the treatment of overactive muscles, overactive exocrine glands and, most recently, non-muscular pain conditions. Autonomic conditions treated with BoNT include achalasia, gastroparesis, sphincter of Oddi spasms, and unspecific esophageal spasms in gastroenterology and prostate disorders in urology. BoNT's use for autonomic conditions related to neurology includes various forms of bladder dysfunction (detrusor sphincter dyssynergia, idiopathic detrusor overactivity, neurogenic detrusor overactivity, urinary retention and bladder pain syndrome), pelvic floor disorders (pelvic floor spasms and anal fissures), hyperhidrosis (axillary, palmar, and plantar hyperhidrosis, diffuse sweating, Frey's syndrome) and hypersalivation (hypersalivation in Parkinsonian syndromes, motor neuron disease, neuroleptic use, and cerebral palsy). Hyperhidrosis, hypersalivation, some forms of bladder dysfunction and pelvic floor disorders can easily be treated by neurologists. Most bladder dysfunctions require cooperation with urology departments.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22878428     DOI: 10.1007/s00415-012-6615-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  175 in total

1.  Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement.

Authors:  D Reddihough; C E Erasmus; H Johnson; G M W McKellar; P H Jongerius
Journal:  Eur J Neurol       Date:  2010-08       Impact factor: 6.089

2.  A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity.

Authors:  Arun Sahai
Journal:  BJU Int       Date:  2006-02       Impact factor: 5.588

3.  Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results.

Authors:  S Hajebrahimi; W Altaweel; J Cadoret; E Cohen; J Corcos
Journal:  Can J Urol       Date:  2005-02       Impact factor: 1.344

4.  Efficacy and duration of botulinum toxin treatment for drooling in 131 children.

Authors:  Arthur R T Scheffer; Corrie Erasmus; Karen van Hulst; Jacques van Limbeek; Peter H Jongerius; Frank J A van den Hoogen
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-09

5.  Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions.

Authors:  Hann-Chorng Kuo
Journal:  Urology       Date:  2006-01-25       Impact factor: 2.649

6.  Botulinum toxin a for idiopathic detrusor overactivity.

Authors:  Kwok Ying Lie; Michael Y C Wong; Lay Guat Ng
Journal:  Ann Acad Med Singap       Date:  2010-09       Impact factor: 2.473

7.  Repeated botulinum toxin type A injections to treat patients with Frey syndrome.

Authors:  Remco de Bree; Jeff E Duyndam; Dirk J Kuik; C René Leemans
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-03

8.  Ultrasound-guided submandibular gland injection of botulinum toxin for hypersalivation in cerebral palsy.

Authors:  Neshe Sriskandan; Andrew Moody; David C Howlett
Journal:  Br J Oral Maxillofac Surg       Date:  2009-04-15       Impact factor: 1.651

9.  Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia.

Authors:  Marcus Riccabona; Mark Koen; Monica Schindler; Beckers Goedele; Armin Pycha; Lukas Lusuardi; Stuart B Bauer
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

10.  Nonsurgical treatment of chronic anal fissure: nitroglycerin and dilatation versus nifedipine and botulinum toxin.

Authors:  Philippe Tranqui; Daniel C Trottier; Charles Victor; Joel B Freeman
Journal:  Can J Surg       Date:  2006-02       Impact factor: 2.089

View more
  9 in total

1.  Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis.

Authors:  Pariessa D Dadgardoust; Raymond L Rosales; Ria Monica Asuncion; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2019-01-02       Impact factor: 3.575

2.  Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.

Authors:  Zdravko Lacković; Boris Filipović; Ivica Matak; Zsuzsanna Helyes
Journal:  Br J Pharmacol       Date:  2016-01       Impact factor: 8.739

Review 3.  Botulinum Toxin as a Pain Killer: Players and Actions in Antinociception.

Authors:  Dong-Wan Kim; Sun-Kyung Lee; Joohong Ahnn
Journal:  Toxins (Basel)       Date:  2015-06-30       Impact factor: 4.546

Review 4.  Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development.

Authors:  Christine Rasetti-Escargueil; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2020-12-22       Impact factor: 4.546

Review 5.  Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications.

Authors:  Numa Piot; F Gisou van der Goot; Oksana A Sergeeva
Journal:  Toxins (Basel)       Date:  2021-01-06       Impact factor: 4.546

6.  Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E.

Authors:  Sebastian Miethe; Christine Rasetti-Escargueil; Arnaud Avril; Yvonne Liu; Siham Chahboun; Hannu Korkeala; Christelle Mazuet; Michel-Robert Popoff; Thibaut Pelat; Philippe Thullier; Dorothea Sesardic; Michael Hust
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

Review 7.  Dermatological problems of the puberty.

Authors:  Beata Bergler-Czop; Ligia Brzezińska-Wcisło
Journal:  Postepy Dermatol Alergol       Date:  2013-06-20       Impact factor: 1.837

8.  Botulinum toxin type A enhances the inhibitory spontaneous postsynaptic currents on the substantia gelatinosa neurons of the subnucleus caudalis in immature mice.

Authors:  Seon-Hui Jang; Soo-Joung Park; Chang-Jin Lee; Dong-Kuk Ahn; Seong-Kyu Han
Journal:  Korean J Physiol Pharmacol       Date:  2018-08-27       Impact factor: 2.016

9.  Guideline for the management of neurogenic bowel dysfunction in spinal cord injury/disease.

Authors:  Ines Kurze; Veronika Geng; Ralf Böthig
Journal:  Spinal Cord       Date:  2022-03-25       Impact factor: 2.473

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.